Neuren Pharmaceuticals Limited (NURPF) Investment Research Dashboard
About Neuren Pharmaceuticals Limited (NURPF) stock analysis
Get live NURPF stock price $13.46, comprehensive Neuren Pharmaceuticals Limited stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time NURPF stock data and investment insights.
Loading chart data...
Neuren Pharmaceuticals Limited (NURPF) Overview
Neuren Pharmaceuticals Limited (NURPF) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, NURPF trades at $13.46 with a market capitalization of 1.71B . Over the past 52 weeks, NURPF has traded between $7.70 and $14.80 , with the current price positioned at approximately 81% of this range . The stock current...
Key Takeaways
- Operates in the Healthcare sector (Biotechnology)
- Market cap: 1.71B
- Current price: $13.46
- 52-week range: $7.70 - $14.80
- P/E ratio: 86.64
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of treatments for neurological conditions. Their leading therapeutic compound, trofinetide, is currently undergoing pivotal (Phase III) clinical trials for ...
Company Information
- CEO
- Jonathan Charles Pilcher
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
Contact Information
- Website
- https://www.neurenpharma.com
- Address
- Suite 1.01, 117 Camberwell Road
- Country
- AU
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 86.6)
✓ Higher growth potential with elevated volatility (Beta: 1.62)
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Neuren Pharmaceuticals Limited shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Neuren Pharmaceuticals Limited
- ⚠Investors should consider how Neuren Pharmaceuticals Limited fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 86.6) requires strong growth to justify
Market Cap
1.71B
P/E Ratio (TTM)
86.64
Beta
1.62
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare NURPF with peer companies:
- Price
- $0.33+0.00% (1D)
- Market cap
- 13.46M
- Price
- $25.57-1.31% (1D)
- Market cap
- 406.38M
- Price
- $2.68+0.00% (1D)
- Market cap
- 77.68M
- Price
- $44.96+0.00% (1D)
- Market cap
- 8.19B
- Price
- $2.04-1.92% (1D)
- Market cap
- 367.38M
- Price
- $83.86+0.01% (1D)
- Market cap
- 8.88B
- Price
- $5.53-8.75% (1D)
- Market cap
- 76.79M
- Price
- $3.02+0.33% (1D)
- Market cap
- 108.71M
- Price
- $53.76+1.94% (1D)
- Market cap
- 3.84B
- Price
- $0.71+0.00% (1D)
- Market cap
- 45.38M
- Price
- $47.89-1.64% (1D)
- Market cap
- 2.76B
- Price
- $3.18+0.00% (1D)
- Market cap
- 185.19M
- Price
- $10.07-1.37% (1D)
- Market cap
- 322.22M
- Price
- $18.71-5.89% (1D)
- Market cap
- 1.55B
- Price
- $1.33+0.76% (1D)
- Market cap
- 65.46M
- Price
- $3.83-4.36% (1D)
- Market cap
- 143.68M
- Price
- $6.69+0.45% (1D)
- Market cap
- 2.32B
- Price
- $5.42+5.86% (1D)
- Market cap
- 19.58M
- Price
- $11.62-3.25% (1D)
- Market cap
- 1.01B
- Price
- $4.57-1.08% (1D)
- Market cap
- 14.68M
- Price
- $54.60-1.62% (1D)
- Market cap
- 7.88B
- Price
- $1.10-6.78% (1D)
- Market cap
- 58.66M
- Price
- $49.37+0.90% (1D)
- Market cap
- 5.92B
- Price
- $7.29+1.96% (1D)
- Market cap
- 49.44M
- Price
- $14.00+0.00% (1D)
- Market cap
- 1.00B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
80/100 ⭐⭐⭐⭐⭐
- Overall
- +0.7%
- NYSE
- +0.6%
- NASDAQ
- +0.7%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +2.2% | +5.7% | +6.1% | 19.3 | 98/100⭐⭐⭐⭐⭐ |
| Communication Services | +1.4% | +2.9% | +4.3% | 22.2 | 86/100⭐⭐⭐⭐⭐ |
| Healthcare | +0.7% | +3.3% | +3.5% | 24.1 | 80/100⭐⭐⭐⭐⭐ |
| Basic Materials | +0.4% | +1.1% | -0.2% | 25.2 | 56/100⭐⭐⭐⭐ |
| Consumer Defensive | -0.2% | +1.7% | +1.2% | 29.7 | 56/100⭐⭐⭐⭐ |
| Real Estate | -0.5% | -0.1% | -1.6% | 29.2 | 43/100⭐⭐⭐ |
| Energy | -2.1% | -5.8% | -5.1% | 19.1 | 39/100⭐⭐ |
| Utilities | -1.0% | -3.0% | -5.9% | 26.8 | 28/100⭐⭐ |
| Industrials | +0.6% | +1.7% | -11.2% | 30.1 | 26/100⭐⭐ |
| Consumer Cyclical | +0.5% | -0.4% | -6.3% | 43.0 | 21/100⭐ |
| Technology | +0.6% | -2.3% | -9.6% | 40.7 | 17/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-29.